Juan Bautista, MD
General Practice · Fresno, CANPI 1164713194
Payments from drug & device makers
Across 91 payments — averaging $61.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$3K
- Merz North America, Inc.$1K
- Amarin Pharma, Inc.$298
- Galderma Laboratories, L.p.$269
- AbbVie$210
- Amgen$199
- plus $877 from 20 others
What the payments were for
- Food & beverage$2,87751%
- Education$2,72049%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 3 | $2,720 |
| Merz North America, Inc. | 13 | $1,025 |
| Amarin Pharma, Inc. | 18 | $298 |
| Galderma Laboratories, L.p. | 2 | $269 |
| AbbVie(2 entities) | 11 | $210 |
| Amgen | 5 | $199 |
| Revance Therapeutics, Inc. | 4 | $168 |
| Johnson & Johnson | 1 | $125 |
| Novartis | 6 | $95 |
| GSK | 6 | $86 |
| Novo Nordisk | 3 | $58 |
| Merck | 3 | $42 |
| Saluda Medical Americas, Inc. | 1 | $35 |
| Exact Sciences | 1 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Dexcom, Inc. | 2 | $31 |
| Indivior Inc. | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Nevro Corp. | 1 | $17 |
| Vertiflex, Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Biocryst US Sales Co., LLC | 1 | $14 |
| Mannkind Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,597 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 31 | $50,532 |
| OzempicSemaglutide | 40 | $44,267 |
| RybelsusSemaglutide | 11 | $20,564 |
| LinzessLinaclotide | 22 | $15,570 |
| XareltoRivaroxaban | 13 | $12,915 |
| JardianceEmpagliflozin | 11 | $12,764 |
| FarxigaDapagliflozin Propanediol | 15 | $10,371 |
| JanuviaSitagliptin Phosphate | 12 | $8,511 |
| VascepaIcosapent Ethyl | 14 | $7,377 |
| Doxepin Hcl | 15 | $4,901 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,297 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $2,104 |
| ProgesteroneProgesterone, Micronized | 17 | $1,065 |
| Atorvastatin Calcium | 81 | $620 |
| Gabapentin | 38 | $612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $58 | $64,83251 claims |
| Lilly USA, LLCMounjaro | $33 | $50,53231 claims |
| AbbVieLinzess | $210 | $15,57022 claims |
| Johnson & JohnsonXarelto | $125 | $12,91513 claims |
| AstraZenecaFarxiga | $16 | $10,37115 claims |
| MerckJanuvia | $42 | $8,51112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Fresno
- Ryan DunlopFresno$151K
- Hipolito MarianoFresno$133K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.